The All India Institute of Medical Sciences (AIIMS) has announced the conduct of human clinical trials of the indigenously developed Covid-19 vaccine candidate Covaxin from July 20.
Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS told news agency ANI that an ethics committee had approved the trials. The institute will select healthy participants with no comorbidities and without a history of Covid-19. The age group of the study population is 18 to 55 years. This would be a randomised, double-blind, placebo-controlled clinical trial. 
In the first and second phase AIIMS Delhi will choose only 100 participants out of 375 volunteers and the remaining will participate at other sites.
DCGI recently gave a green signal for human clinical trials for Covid-19 vaccine candidate Covaxin, which has been developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV). “We have already registered a few volunteers for the trial. From Monday onwards, our team will start their health screening before giving them vaccination,” he said.
It may be noted that there are 12 places where the trial for Covaxin is taking place as per the Indian Council for Medical Research (ICMR).
Trials have started at AIIMS, Patna and few other places.

The institute will select healthy participants with no comorbidities and without a history of Covid-19.